Welcome to Marit Inngjerdingen's research group:

Lymphocyte activation group

Marit Inngjerdingen<br>Group leader
Marit Inngjerdingen
Group leader


The group investigates mechanisms of how tumor cells evade and/or suppress the immune system, with a particular focus on NK cells and acute leukemia. NK cells contribute to protection from cancer development, but NK cell responses are often low in cancer patients. Better understanding of how lymphocyte activation is regulated in context of cancer could aid development of improved immunotherapies directed at increasing lymphocyte sensitivity towards malignant cells.



  • Longitudinal studies of NK cells in pediatric patients with ALL or AML in collaboration with the Department of Children, Oslo University Hospital, aiming at correlating NK cell responses and/or receptor repertoires with disease outcome.
  • In-depth mechanistic studies of how leukemia blasts evade and suppress the immune system using in vivo rat models of T-ALL and AML. Projects include tailoring NK cells for immunotherapy, and investigations on how soluble ligands and exosomes released from leukemic blasts affect NK cell tumor immunosurveillance.
  • Evaluation of exosomes as early prognostic markers for risk stratification of pediatric acute leukemia.
  • Characterization of intracellular signaling cascades in human T cells and NK cells in health and disease.

Contact information:
Marit Inngjerdingen, PhD                          
Department of Immunology
Tel: +47 23 07 37 69 / 95 06 39 29
E-mail: mariti@medisin.uio.no